Acetylcholine Receptor Binding Antibody
Also known as: ACHRBIN
Use
Approximately 85-90% of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR). The presence of these antibodies is significant in the diagnosis of MG, a condition where the body's immune system attacks communication sites between nerves and muscles, leading to muscle weakness. This test specifically measures the binding antibodies, which can activate complement and result in the loss of AChR, impacting diagnostic and therapeutic plans for patients with MG.
Special Instructions
The test requires prompt specimen preparation with separation from cells within 2 hours. It is primarily indicated for initial diagnostic testing for myasthenia gravis. An alternative panel including additional antibody tests is available for comprehensive assessment.
Limitations
Around 10-15% of individuals clinically diagnosed with myasthenia gravis do not show measurable levels of binding, blocking, or modulating antibodies using this assay. The assay has not been cleared or approved by the FDA but is conducted in a CLIA-certified laboratory, reflecting its status as a laboratory-developed test. Results should be interpreted in conjunction with clinical findings and other diagnostic tests.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 11034-6
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells as soon as possible or within 2 hours of collection.
Storage Instructions
Refrigerated storage is preferred. Avoid repeated freeze/thaw cycles.
Causes for Rejection
Plasma, contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |